home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Fishing for New Leukaemia Drugs

  January, 30 2009 18:13
your information resource in human molecular genetics
New potential drug targets for acute myelogenous leukaemia (AML) are reported in a paper published online in Nature Chemical Biology.

Even with aggressive treatment, AML typically recurs within two years, because leukemic stem cells are thought to be resistant to the drugs used to treat the disease. It may therefore be necessary to design drugs targeting these stem cells specifically and then combine them with current treatments.

Randall Petersen and colleagues identified drug leads for modulating these leukemic stem cells by high-throughput screening of chemical libraries in zebrafish. The authors discovered that a known non-steroidal anti-inflammatory drug could block the effect of a cancer causing gene on stem cell differentiation.

The results identify a pathway in AML stem cells that might lead to new targets for developing AML therapies. The research also demonstrates the potential of zebrafish for identifying drug leads for complex diseases.

Author contact:

Randall T. Peterson (Massachusetts General Hospital, Charlestown MA, USA)
E-mail: peterson@cvrc.mgh.harvard.edu

Abstract available online.

(C) Nature Chemical Biology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.